Tag - SGLT2 inhibitors

  • Home
  • Tag -
  • SGLT2 inhibitors

Kidney International® publishes new CKD remission paradigm, presented simultaneously at Kidney Week 2025

Kidney International® (KI) published "From progression to remission: a new paradigm for success in chronic kidney disease," by Nav Tangri, David Cherney, Katherine Tuttle, and Vlado Perkovic. The article was released at the same time as its presentation at ASN Kidney Week, increasing the study's visibility and reinforcing its significance to the global kidney community.  Read the article in KI  The research emphasizes a shift in...

November 10, 2025Journals, NewsRead more...

Better outcomes for interconnected conditions: The ISN’s CKM Initiative on World Heart Day 

As we observe World Heart Day, today, September 29, the ISN underscores the critical intersection of cardiovascular and kidney health through its Cardio-Kidney-Metabolic (CKM) Initiative.   The ISN encourages healthcare professionals worldwide to integrate the CKM tools into their practice. By doing so, clinicians can refine their approach to treating patients with overlapping cardiovascular, kidney, and...

September 29, 2025Initiatives, ISN Toolkits, NewsRead more...

Enhance patient care with cardio-kidney-metabolic resources 

Are you making the most of the latest clinical tools from the multi-society Cardio-Kidney-Metabolic (CKM) Initiative led by the ISN?  The CKM Initiative addresses gaps in therapy, management, and implementation — supporting clinicians and advancing care for patients with CKM conditions. It includes an interactive CKM roadmap to guide the management of patients with cardio-kidney-metabolic...

March 24, 2025Initiatives, ISN Toolkits, NewsRead more...

Access the New ISN Toolkit on Optimizing SGLT2i Therapy and a Brand New Tool on MRAs 

The Optimization of SGLT2i Therapy Toolkit* is the latest educational offering from a multi-society cardio-kidney-metabolic initiative led by the ISN. This initiative offers resources for advancing the prevention and management of cardio-kidney-metabolic complications. The toolkit highlights the crucial role of SGLT2 inhibitors in improving outcomes for patients with both kidney and cardiovascular diseases.  The SGLT2i...

February 3, 2025Initiatives, ISN Toolkits, NewsRead more...

Explore the Latest ISN Global Trials Focus Selections Featuring a “Trial of the Month” on the Effects of Semaglutide on CKD in People With Type 2 Diabetes

ISN-ACT Global Trials Focus editorial team member Michele Provenzano summarizes the design and outcomes of the latest "Trial of the Month" featured in ISN-ACT Global Trials Focus. The "Trial of the Month" is available in several languages, now including German. Read all global trial selections from the ISN-ACT initiative here. In addition, in the ISN 'Guide for Everyone' series,...

September 2, 2024News, ResearchRead more...

Hear From Global Experts on Equitable Access to Innovative Therapies

Aligning with the 2024 World Kidney Day theme, "Advancing equitable access to care and optimal medication practice," Nature Reviews Nephrology has published an editorial on innovative therapies for diabetic kidney disease (DKD). Five global experts* from different world regions, including authors of the 2024 World Kidney Day scientific editorial, discuss barriers that must be...

July 15, 2024Advocacy, Research, World Kidney DayRead more...

Advancing Knowledge on CKD Treatment and Prevention: The ISN Supports Scientific Meeting in Macedonia

Delegates enjoy the program In April, the ISN supported the "7th Congress of the Macedonian Society of Nephrology, Dialysis and Artificial Organs (MSNDTAO) With International Participation" in Skopje, Macedonia, through its Continuing Medical Education Program (CME). The scientific program included an ISN CME course, "From Prevention to Best Treatment Options in CKD." Dr. Goce Spasovski presents on...

May 21, 2024CME, Grants, NewsRead more...

Explore the ISN Global Trials Focus Selection for February and March, Featuring a “Trial of the Month” on the Efficacy and Safety of Aldosterone Synthase Inhibition 

ISN-ACT Global Trials Focus editorial team member Neeru Agarwal summarizes the design and outcomes of the latest ISN-ACT Global Trials Focus "Trial of the Month."  The "Trial of the Month" is available in several languages, now including German. Read all global trial selections from the ISN-ACT initiative here. In addition, selected clinical trials are demystified for the layperson.  Part of the...

April 23, 2024News, ResearchRead more...

ISN-Endorsed Events With ISN Participation in April – Apply for ISN Endorsement for Your Event!

The ISN endorses high-quality events within the kidney care community. Whether your event is big or small, if it addresses region-relevant topics, it could qualify for our endorsement. Apply for ISN endorsement for enhanced visibility, scientific merit, and educational impact. Discover all the benefits of ISN-endorsed meetings and how to apply here April 25-28, 2024               Jakarta,...

April 2, 2024ISN Participates, NewsRead more...

Beyond Blood Sugar: Ele Ferrannini on the Basis for the Transformative Power of SGLT2 Inhibitors for Kidney Disease Management at WCN’24

Ele Ferrannini, a professor of Internal Medicine at the University of Pisa and a senior research associate at the National Research Council Institute of Clinical Physiology, will present the plenary talk "Insights Into SGLT2 Inhibitors: A Story of Discovery" at WCN'24 in Hall A on Tuesday, April 16 at 11 a.m. Argentina time. Register for...

December 11, 2023News, WCNRead more...